Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting

Executive Summary

• Kane Biotech presented new clinical and scientific data at the Innovations in Wound Healing (IWH) Annual Meeting, highlighting case‑study outcomes for its revyve® wound care portfolio.
• FDA 510(k) clearance and Health Canada approval of revyve Antimicrobial Wound Gel and Spray were reiterated, underscoring regulatory status.
• The company shared market adoption insights showing integration of its products into health‑system care pathways.

Key Details

• Conference: Innovations in Wound Healing (IWH) Annual Meeting, Key West, Florida, Dec 11‑14 2025.
• Clinical Highlights:
• Case studies demonstrated improved healing trajectories in chronic wounds using Kane’s advanced wound gel platform.
• Efficacy shown across multiple sites, dressing types, and application frequencies, including highly exudative wounds.
• New data on a Chronic Radiation‑Induced Achilles Ulcer indicated the gel supports healing in radiation‑compromised tissue where conventional therapies often fail.
• Results in Hidradenitis Suppurativa (HS) illustrated revyve®’s ability to reduce infection burden and improve patient outcomes.
• Regulatory Status:
• revyve Antimicrobial Wound Gel – FDA 510(k) cleared, Health Canada approved.
• revyve Antimicrobial Wound Gel Spray – FDA 510(k) cleared.
• Market Adoption Insights: Presentation included evidence of product integration into care pathways and measurable value delivery to health systems.
• Link to Presentations: https://kanebiotech.com/publications-posters/ (access provided in release).

Notable Quotes

“These presentations highlight Kane Biotech’s dedication to advancing wound care innovation across a spectrum of challenging conditions,” said Dr. Robert B. Huizinga, Interim CEO of Kane Biotech.

Materiality Assessment: Non‑Material – Positive (the release provides positive clinical updates and regulatory confirmations but does not contain new financial or transactional information).